Ioana Molnar

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Venues

Breast cancer research and treatment

F1000Research

BMC cancer

Genes, chromosomes & cancer

Centre Jean Perrin

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Centre Jean Perrin

France

Biostatistician

Publications

Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Angeline Ginzac, Marie-Céleste Ferreira, Anne Cayre, Clément Bouvet, Julian Biau, Ioana Molnar, Nicolas Saroul, Nathalie Pham-Dang, Xavier Durando, Maureen Bernadach
Prediction of residual disease using circulating DNA detection after potentiated radiotherapy for locally advanced head and neck cancer (NeckTAR): a study protocol for a prospective, multicentre trial. BMC cancer 23 (1) (2023)
Angeline Ginzac, Guillaume Dupic, Lucie Brun, Ioana Molnar, Mélanie Casile, Xavier Durando, Pierre Verrelle, Jean-Jacques Lemaire, Toufic Khalil, Julian Biau
Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial. BMC cancer 21 (1) (2021)
Céleste Pinard, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, Xavier Durando
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer. F1000Research 9 (2020)
Céleste Pinard, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, Xavier Durando
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer. F1000Research 9 (2020)
Mathias Cavaillé, Nancy Uhrhammer, Maud Privat, Flora Ponelle-Chachuat, Mathilde Gay-Bellile, Mathis Lepage, Ioana Molnar, Sandrine Viala, Yannick Bidet, Yves-Jean Bignon
Analysis of 11 candidate genes in 849 adult patients with suspected hereditary cancer predisposition. Genes, chromosomes & cancer 60 (2) (2020)
Céleste Pinard, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, Xavier Durando
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer. F1000Research 9 (2020)

Ioana Molnar.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Ioana Molnar